Disaggregated Revenues

3 Months Ended

Mar. 31, 2023

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):

	Three Months Ended March 31,
	2023		2022
	(unaudited)
Net product sales
Trokendi XR	$	34,790	$	62,832
Oxtellar XR	28,915		27,521
GOCOVRI	26,010		22,601
Qelbree	25,782		8,283
APOKYN	17,209		18,448
Other(1)	7,869		7,779
Total net product sales	$	140,575	$	147,464
Royalty revenues	13,189		5,042
Total revenues	$	153,764	$	152,506

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Trokendi XR accounted for 25% and 43% of the Company’s total net product sales for the three months ended March 31, 2023 and 2022, respectively.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total net product sales and collectively accounted for more than 75% of our total net product sales in 2023 and 2022.

The Company recognized noncash royalty revenue of $2.3 million and $2.2 million for the three months ended March 31, 2023 and 2022, respectively. Refer to Note 15, Commitments and Contingencies.